Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
conventional treatment group:conventional treatment
conventional treatment combined with hymecromone tablets group:conventional treatment combined with hymecromone tablets treatment
Sponsors
Shanghai Public Health Clinical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All inclusion criteria must be met to qualify for inclusion: 1. The age should be over 18 years old and under 70 years old, with no gender limit. Those who meet the diagnostic criteria of clinical pneumonia 2. According to the clinical diagnosis of viral pneumonia: (1) Fever (oral temperature >= 38 degrees C, or axillary temperature >= 37.5 degrees C; or fever history within 24 hours before baseline, whether taking antipyretics or not; or having fever symptoms within 48 hours before baseline), with or without respiratory symptoms (respiratory rate > 30 beats / min); (2) White blood cell count was normal or low, with or without thrombocytopenia; (3) Chest imaging (chest CT): unilateral or bilateral chest imaging showed multiple (at least 2 lesions) or diffuse patchy or ground glass infiltration (with or without consolidation); 3. SARS-COV-2 is positive for pathogens. After respiratory virus screening, oropharyngeal test pieces with one or more virus nucleic acid positive can be selected into the group. The SARS-COV-2 in the samples were further evaluated by qPCR according CT valune; 4. Prior to the start of the study, a written informed letter should be signed (for the incompetent subjects, if the researcher thinks that it is in their own interests to participate in the trial, the informed consent shall be signed by the legal guardian of the subject, and it shall be explained in the original medical record and other relevant documents).
Exclusion criteria
Exclusion criteria: Those who meet any of the following criteria shall not be included in the group: 1. There were serious noninfectious pulmonary diseases, including pulmonary tumor, pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophilic infiltration and pulmonary vasculitis; 2. Severe liver and kidney dysfunction: (1) ALT and AST value were more than 10 times higher than the upper limit of normal value; (2) Serum creatinine value was more than 1.5 times higher than the upper limit of normal value; (3) Total bilirubin was more than 2 times the upper limit of normal value; 3. Patients with biliary obstruction; 4. Pregnant women (urine or serum pregnancy test positive) or lactating women; 5. Other subjects considered unsuitable by the researchers for this trial, or the researchers think that there may be any situation that may increase the risk of subjects or interfere with the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hyaluronic acid;Virus negative time; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD44 factor;VII factor activity;uPA / uPAR dynamic change; | — |
Countries
China
Contacts
Public ContactLu Hongzhou, Yu Wenqiang
Shanghai Public Health Clinical Center
Outcome results
None listed